David Rabago1, Laura van Leuven1, Lane Benes2, Luke Fortney3, Andrew Slattengren4, Jessica Grettie5, Marlon Mundt1. 1. 1 The Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health , Madison, WI. 2. 2 Department of Medicine, University of Chicago , Chicago, IL. 3. 3 McKee Clinic Family Medicine , Meriter Unity Point Health, Madison, WI. 4. 4 Department of Family Medicine and Community Health, Broadway Family Medicine Clinic, University of Minnesota Medical School , Minneapolis, MN. 5. 5 Wisconsin Center for Education Research, University of Wisconsin , Madison, WI.
Abstract
OBJECTIVE: Randomized and open-label studies assessing prolotherapy for knee osteoarthritis have found quantitative improvement on the validated Western Ontario McMaster University Osteoarthritis Index (WOMAC) compared with baseline status and control therapies. This study assessed the qualitative response of participants receivingprolotherapy, an injection-based complementary treatment for symptomatic knee osteoarthritis (OA). DESIGN: Qualitative study using semi-structured in-depth interviews at 52 weeks after enrollment; transcribed responses were discussed by coauthors to identify themes; disagreement was resolved by consensus. SETTING: Outpatient. PARTICIPANTS: Twenty-two participants treated with prolotherapy for symptomatic knee OA who were exited from three randomized and open-label studies. INTERVENTIONS:Intra- and extra-articular hypertonic dextrose injection (prolotherapy). MAIN OUTCOME MEASURES: Patient narrative and composite WOMAC questionnaire (0-100 points) scores. RESULTS: Participants had baseline demographic and knee OA severity similar to those of participants in three prior intervention trials, as well as similar robust follow-up WOMAC score change (19.9 ± 12.6 points), suggesting a representative subsample. Seven themes were identified from participant narratives: (1) improvement in knee-specific quality of life (n = 18), (2) safety and comfort, (3) pretreatment counseling enhanced treatment adherence and optimism, (4) overall positive experience with prolotherapy, (5) limited response to prolotherapy (n = 4), (6) consistency with anecdotal clinical prolotherapy experience; and (7) functional improvement without pain reduction. CONCLUSIONS: Most participants reported substantially improved knee-specific effects, resulting in improved quality of life and activities of daily living; four participants reported minimal or no effect. Clear, complete description of procedural rationale may enhance optimism about and adherence to treatment appointments.
RCT Entities:
OBJECTIVE: Randomized and open-label studies assessing prolotherapy for knee osteoarthritis have found quantitative improvement on the validated Western Ontario McMaster University Osteoarthritis Index (WOMAC) compared with baseline status and control therapies. This study assessed the qualitative response of participants receiving prolotherapy, an injection-based complementary treatment for symptomatic knee osteoarthritis (OA). DESIGN: Qualitative study using semi-structured in-depth interviews at 52 weeks after enrollment; transcribed responses were discussed by coauthors to identify themes; disagreement was resolved by consensus. SETTING:Outpatient. PARTICIPANTS: Twenty-two participants treated with prolotherapy for symptomatic knee OA who were exited from three randomized and open-label studies. INTERVENTIONS: Intra- and extra-articular hypertonicdextrose injection (prolotherapy). MAIN OUTCOME MEASURES: Patient narrative and composite WOMAC questionnaire (0-100 points) scores. RESULTS:Participants had baseline demographic and knee OA severity similar to those of participants in three prior intervention trials, as well as similar robust follow-up WOMAC score change (19.9 ± 12.6 points), suggesting a representative subsample. Seven themes were identified from participant narratives: (1) improvement in knee-specific quality of life (n = 18), (2) safety and comfort, (3) pretreatment counseling enhanced treatment adherence and optimism, (4) overall positive experience with prolotherapy, (5) limited response to prolotherapy (n = 4), (6) consistency with anecdotal clinical prolotherapy experience; and (7) functional improvement without pain reduction. CONCLUSIONS: Most participants reported substantially improved knee-specific effects, resulting in improved quality of life and activities of daily living; four participants reported minimal or no effect. Clear, complete description of procedural rationale may enhance optimism about and adherence to treatment appointments.
Entities:
Keywords:
dextrose injection; knee osteoarthritis; prolotherapy; qualitative study; regenerative medicine
Authors: David Rabago; Jeffrey J Patterson; Marlon Mundt; Richard Kijowski; Jessica Grettie; Neil A Segal; Aleksandra Zgierska Journal: Ann Fam Med Date: 2013 May-Jun Impact factor: 5.166
Authors: Andrew J Vickers; Angel M Cronin; Alexandra C Maschino; George Lewith; Hugh MacPherson; Nadine E Foster; Karen J Sherman; Claudia M Witt; Klaus Linde Journal: Arch Intern Med Date: 2012-10-22
Authors: Regina Ws Sit; Vincent Ch Chung; Kenneth D Reeves; David Rabago; Keith Kw Chan; Dicken Cc Chan; Xinyin Wu; Robin St Ho; Samuel Ys Wong Journal: Sci Rep Date: 2016-05-05 Impact factor: 4.379
Authors: Alex Tang Zhao; Cassidy J Caballero; Linh T Nguyen; Hunter C Vienne; Christopher Lee; Alan D Kaye Journal: Orthop Rev (Pavia) Date: 2022-05-31